Conflict of interest: D. Ivy reports grants from the National Institutes of Health and Janssen, consultancy fees, and support for attending meetings from Bayer, Merck and Janssen, as well as a leadership role with the Association of Pediatric Pulmonary Hypertension. E.B. Rosenzweig reports grants from Bayer, Janssen, and Insmed and is Director of PPHNet and Board Member of Team Phenomenal Hope. S.H. Abman reports consultancy fees from Chiasi and Oak Hills Bio, as well as leadership roles with BPD Collaborative and Pediatric Pulmonary Hypertension Network. M. Beghetti reports consultancy fees from Actelion/Janssen, MSD, Merck, Gossamer, GSK and Orpha, payment or honoraria for lectures, presentations, manuscript writing or educational events, and support for attending meetings from Actelion/Janssen and MSD, and participation on a data safety monitoring board or advisory board with GSK, Actelion/Janssen, Gossamer, Altavant and MSD. D. Bonnet reports consultancy fees from Janssen, MSD and Novartis, and participation on a data safety monitoring board or advisory board with Lupin. J.M. Douwes has no potential conflicts of interest to disclose. A. Manes reports grants from Janssen/Actelion and Merck, payment or honoraria for lectures, presentations, manuscript writing, or educational events from Janssen/Actelion, support for attending meetings from Dompè, and participation on a data safety monitoring board or advisory board with AOP Health Italy. R.M.F. Berger reports grants from Johnson & Johnson, consultancy fees from Johnson & Johnson, GSK and Ferrer, payment or honoraria for lectures, presentations, manuscript writing or educational events from Johnson & Johnson, Ferrer, AOP, MSD, Heart Medical, Occlutech Salveo, Bayer and Gossamerbio, participation on a data safety monitoring board or advisory board with MSD, and leadership roles with TOPP-registry, PPHNet and the ESC/ERS 2022 guidelines for diagnosis and treatment of pulmonary hypertension task force.